Pregnancy Surveillance Using a Health Insurance Database

WEBINAR | Recorded November 12, 2008
Let’s talk about how to determine the effect of drugs taken during pregnancy.

Monitoring pregnancy outcomes for women exposed to drugs, especially for newly marketed drugs, is important as it provides data to inform future clinical decisions about whether or not to use a particular drug during pregnancy. Large automated health insurance databases are an excellent resource to answer questions about the effect of maternal drug exposures on infants, and offer the following advantages over more traditional pregnancy surveillance methods:
  • The size of the source data, which allows fairly rare exposures to be related to outcomes among infants
  • Automated capture of both drug exposure and pregnancy outcome information through insurance claims, which diminishes issues of selective reporting
  • The ability to ascertain pregnancy outcomes following exposure to any prescription medication, ensuring the surveillance precedes knowledge of the outcome.
Register today for this informative webinar presented by members of i3 Drug Safety’s scientific team. Join us online as they review:
  • i3 Drug Safety's experience in conducting pregnancy surveillance studies
  • Published literature that illustrates the utility of a health insurance database for addressing pregnancy surveillance questions
  • i3 Drug Safety's approach to addressing questions in this area
We invite you to view this complimentary interactive discussion where you’ll have the opportunity to send us your questions and comments during the webinar.

www.i3drugsafety.com


Presenters:

Terri Madison, PhD, MPH
President, i3 Drug Safety

John D. Seeger, PharmD, DrPH
Senior Scientist, i3 Drug Safety

Learn more about the presenters

 
 
This message was sent by i3 Drug Safety | 5430 Data Court, Suite 200 | Ann Arbor, MI 48108
(800) 765-6089 | info@i3drugsafety.com | www.i3drugsafety.com
© 2008 Ingenix, Inc. | 100-0585–10-21-2008